Genetics of Late‐Onset Alzheimer′s Disease: Update from the Alzgene Database and Analysis of Shared Pathways
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The genetics of late‐onset Alzheimer′s disease (LOAD) has taken impressive steps forwards in the last few years. To date, more than six‐hundred genes have been linked to the disorder. However, only a minority of them are supported by a sufficient level of evidence. This review focused on such genes and analyzed shared biological pathways. Genetic markers were selected from a web‐based collection (Alzgene). For each SNP in the database, it was possible to perform a meta‐analysis. The quality of studies was assessed using criteria such as size of research samples, heterogeneity across studies, and protection from publication bias. This produced a list of 15 top‐rated genes: APOE, CLU, PICALM, EXOC3L2, BIN1, CR1, SORL1, TNK1, IL8, LDLR, CST3, CHRNB2, SORCS1, TNF, and CCR2. A systematic analysis of gene ontology terms associated with each marker showed that most genes were implicated in cholesterol metabolism, intracellular transport of beta‐amyloid precursor, and autophagy of damaged organelles. Moreover, the impact of these genes on complement cascade and cytokine production highlights the role of inflammatory response in AD pathogenesis. Gene‐gene and gene‐environment interactions are prominent issues in AD genetics, but they are not specifically featured in the Alzgene database.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Harold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920 · cited 1×
“Another variant of the APOE gene, e2, has protective effects against the development of AD [20, 21].”
BackgroundSystematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“AlzGene is a web-based synopsis of published association studies on AD [22].”
MethodGenome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease
Rogaeva, E., Meng, Y., Lee, J. H., Gu, Y., Kawarai, T., Zou, F., Katayama, T., Baldwin, C. T., Cheng, R., Hasegawa, H., et al. (2007) · Nature Genetics · doi:10.1038/ng1943 · Cited by 1,167 · cited 2×
“The gene-encoding SorLA, SORL1, was investigated as a susceptibility factor for LOAD in twenty-one case-control samples [54–74].”
BackgroundSystemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139 · cited 2×
“Etanercept, a biological antagonist of TNFalpha, is under evaluation as a therapeutic agent for AD.”
BackgroundLee, J. W., Lee, Y. K., Yuk, D. Y., Choi, D. Y., Ban, S. B., Oh, K. W., & Hong, J. T. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-37 · Cited by 772
Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease
Masliah, E., Mallory, M., Alford, M., DeTeresa, R., Hansen, L. A., McKeel, D. W., & Morris, J. C. (2001) · Neurology · doi:10.1212/wnl.56.1.127 · Cited by 720
Bell, R. D., Sagare, A. P., Friedman, A. E., Bedi, G. S., Holtzman, D. M., Deane, R., & Zlokovic, B. V. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600419 · Cited by 670 · cited 1×
“Clusterin interacts with the soluble form of beta amyloid in animal models of AD and binds soluble beta-amyloid in a specific and reversible manner, forming complexes that cross the blood-brain barrier [27].”
BackgroundAndersen, O. M., Reiche, J., Schmidt, V., Gotthardt, M., Spoelgen, R., Behlke, J., von Arnim, C. A. F., Breiderhoff, T., Jansen, P., Wu, X., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503689102 · Cited by 655
Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo
Cirrito, J. R., Kang, J.-E., Lee, J., Stewart, F. R., Verges, D. K., Silverio, L. M., Bu, G., Mennerick, S., & Holtzman, D. M. (2008) · Neuron · doi:10.1016/j.neuron.2008.02.003 · Cited by 635
Maturation of Autophagic Vacuoles in Mammalian Cells
Eskelinen, E.-L. (2005) · Autophagy · doi:10.4161/auto.1.1.1270 · Cited by 626
Solomon, A., Kivipelto, M., Wolozin, B., Zhou, J., & Whitmer, R. A. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000231980 · Cited by 557
Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease
Li, H., Wetten, S., Li, L., St. Jean, P. L., Upmanyu, R., Surh, L., Hosford, D., Barnes, M. R., Briley, J. D., Borrie, M., et al. (2008) · Archives of Neurology · doi:10.1001/archneurol.2007.3 · Cited by 499
Franke, L., Bakel, H. V., Fokkens, L., de Jong, E. D., Egmont-Petersen, M., & Wijmenga, C. (2006) · The American Journal of Human Genetics · doi:10.1086/504300 · Cited by 476
Anstey, K. J., Mack, H. A., & Cherbuin, N. (2009) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181a2fd07 · Cited by 452
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice
Wyss-Coray, T., Yan, F., Lin, A. H.-T., Lambris, J. D., Alexander, J. J., Quigg, R. J., & Masliah, E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162350199 · Cited by 446 · cited 1×
“Notably, complement inhibition was shown to reduce the clearance of beta amyloid in animal models [50].”
BackgroundInflammatory markers and the risk of Alzheimer disease: The Framingham Study
Tan, Z. S., Beiser, A. S., Vasan, R. S., Roubenoff, R., Dinarello, C. A., Harris, T. B., Benjamin, E. J., Au, R., Kiel, D. P., Wolf, P. A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000263217.36439.da · Cited by 440
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405
Cataldo, A. M., Petanceska, S., Terio, N. B., Peterhoff, C. M., Durham, R., Mercken, M., Mehta, P. D., Buxbaum, J., Haroutunian, V., & Nixon, R. A. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.027 · Cited by 363
Epigenetics, oxidative stress, and Alzheimer disease
Zawia, N. H., Lahiri, D. K., & Cardozo-Pelaez, F. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.02.006 · Cited by 337
Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., Mason, S. M., Paul, S. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.013 · Cited by 308 · cited 1×
“with decrease in APOE levels and beta amyloid due to either inhibited deposition or enhanced clearance [88].”
BackgroundThe interplay of neurotransmitters in Alzheimer's disease
Francis, P. T. (2005) · CNS Spectrums · doi:10.1017/s1092852900014164 · Cited by 302 · cited 1×
“A marked neural loss is reported in cholinergic nuclei in the basal forebrain as opposed to an overactivation of NMDA-mediated glutamatergic pathways [5].”
BackgroundIntrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease
Galimberti, D., Schoonenboom, N., Scheltens, P., Fenoglio, C., Bouwman, F., Venturelli, E., Guidi, I., Blankenstein, M. A., Bresolin, N., & Scarpini, E. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.538 · Cited by 289 · cited 1×
“Cerebrospinal fluid levels of IL-8 were found to be increased in AD and mild cognitive impairment [78].”
BackgroundYu, W. H., Kumar, A., Peterhoff, C., Shapiro Kulnane, L., Uchiyama, Y., Lamb, B. T., Cuervo, A. M., & Nixon, R. A. (2004) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.05.010 · Cited by 279
Corneveaux, J. J., Myers, A. J., Allen, A. N., Pruzin, J. J., Ramirez, M., Engel, A., Nalls, M. A., Chen, K., Lee, W., Chewning, K., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq221 · Cited by 237 · cited 1×
“The gene encoding cr1, chromosome 1 (CR1), was investigated in eleven independent samples [28, 29, 31, 33, 41, 42, 52].”
BackgroundProtection against Alzheimer's disease with apoE ∈2
Talbot, C., Lendon, C., Craddock, N., Shears, S., Morris, J., & Goate, A. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92557-7 · Cited by 225
Genetic Variation and Neuroimaging Measures in Alzheimer Disease
Biffi, A. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.108 · Cited by 222 · cited 2×
“The gene encoding cr1, chromosome 1 (CR1), was investigated in eleven independent samples [28, 29, 31, 33, 41, 42, 52].”
BackgroundAMPH-1/Amphiphysin/Bin1 functions with RME-1/Ehd1 in endocytic recycling
Pant, S., Sharma, M., Patel, K., Caplan, S., Carr, C. M., & Grant, B. D. (2009) · Nature Cell Biology · doi:10.1038/ncb1986 · Cited by 218
Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease
Carrasquillo, M. M., Belbin, O., Hunter, T. A., Ma, L., Bisceglio, G. D., Zou, F., Crook, J. E., Pankratz, V. S., Dickson, D. W., Graff-Radford, N. R., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.147 · Cited by 208 · cited 2×
“The gene encoding cr1, chromosome 1 (CR1), was investigated in eleven independent samples [28, 29, 31, 33, 41, 42, 52].”
BackgroundPeripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes
Rogers, J., Li, R., Mastroeni, D., Grover, A., Leonard, B., Ahern, G., Cao, P., Kolody, H., Vedders, L., Kolb, W. P., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.043 · Cited by 175 · cited 1×
“Levels of beta amyloid targeted by this pathway differed significantly in AD compared to mild cognitive impairment and nondemented elderly controls [51].”
BackgroundNeuroimmunomodulation in the Pathogenesis of Alzheimer’s Disease
Morales, I., Farías, G., & Maccioni, R. B. (2010) · Neuroimmunomodulation · doi:10.1159/000258724 · Cited by 162 · cited 1×
“It has also been suggested that activated microglia may lead to phosphorylation of tau and formation of neurofibrillary tangles [139, 140].”
BackgroundTrougakos, I. P., Lourda, M., Antonelou, M. H., Kletsas, D., Gorgoulis, V. G., Papassideri, I. S., Zou, Y., Margaritis, L. H., Boothman, D. A., & Gonos, E. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1805 · Cited by 160
A Genomewide Screen for Late-Onset Alzheimer Disease in a Genetically Isolated Dutch Population
Liu, F., Arias-Vásquez, A., Sleegers, K., Aulchenko, Y. S., Kayser, M., Sanchez-Juan, P., Feng, B.-J., Bertoli-Avella, A. M., van Swieten, J., Axenovich, T. I., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/518720 · Cited by 156 · cited 2×
“The gene-encoding SorLA, SORL1, was investigated as a susceptibility factor for LOAD in twenty-one case-control samples [54–74].”
BackgroundEvidence for CALM in Directing VAMP2 Trafficking
Harel, A., Wu, F., Mattson, M. P., Morris, C. M., & Yao, P. J. (2008) · Traffic · doi:10.1111/j.1600-0854.2007.00694.x · Cited by 144 · cited 1×
“Gene-gene and gene-environment interactions are prominent issues in AD genetics, but they are not specifically featured in the Alzgene database.”
BackgroundCell “Self‐Eating” (Autophagy) Mechanism in Alzheimer's Disease
Funderburk, S. F., Marcellino, B. K., & Yue, Z. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20161 · Cited by 139
Examination of the current top candidate genes for AD in a genome-wide association study
Feulner, T. M., Laws, S. M., Friedrich, P., Wagenpfeil, S., Wurst, S. H. R., Riehle, C., Kuhn, K. A., Krawczak, M., Schreiber, S., Nikolaus, S., et al. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.141 · Cited by 128
Macrophages in Alzheimer’s disease: the blood-borne identity
Gate, D., Rezai-Zadeh, K., Jodry, D., Rentsendorj, A., & Town, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0422-7 · Cited by 107 · cited 1×
“They could clear beta amyloid via phagocytosis [12].”
BackgroundThe c-Myc-interacting adaptor protein Bin1 activates a caspase-independent cell death program
Elliott, K., Ge, K., Du, W., & Prendergast, G. C. (2000) · Oncogene · doi:10.1038/sj.onc.1203681 · Cited by 106
Kida, E., Choi-Miura, N.-H., & Wisniewski, K. E. (1995) · Brain Research · doi:10.1016/0006-8993(95)00482-6 · Cited by 79
Cuenco, K. T. (2008) · Archives of Neurology · doi:10.1001/archneur.65.12.1640 · Cited by 61
The Role of Microglia in Antibody-Mediated Clearance of Amyloid-Beta from the Brain
Morgan, D. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601821 · Cited by 58
Zou, F., Gopalraj, R. K., Lok, J., Zhu, H., Ling, I.-F., Simpson, J. F., Tucker, H. M., Kelly, J. F., Younkin, S. G., Dickson, D. W., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm365 · Cited by 58
Genetic association of low density lipoprotein receptor and Alzheimer's disease
Gopalraj, R. K., Zhu, H., Kelly, J. F., Mendiondo, M., Pulliam, J. F., Bennett, D. A., & Estus, S. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.09.001 · Cited by 51
APOE epsilon-4 allele and cytokine production in Alzheimer's disease
Olgiati, P., Politis, A., Malitas, P., Albani, D., Dusi, S., Polito, L., De Mauro, S., Zisaki, A., Piperi, C., Stamouli, E., et al. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2344 · Cited by 35 · cited 1×
“Recently, we have reported an association between APOE alleles and IL-1beta levels in patients with AD [157].”
BackgroundSelf-citationFunctional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease
Cheng, D., Huang, R., Lanham, I. S., Cathcart, H. M., Howard, M., Corder, E. H., & Poduslo, S. E. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.024968 · Cited by 33
Sundelöf, J., Sundström, J., Hansson, O., Eriksdotter-Jönhagen, M., Giedraitis, V., Larsson, A., Degerman-Gunnarsson, M., Ingelsson, M., Minthon, L., Blennow, K., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-091594 · Cited by 32
Persistence of and Changes in Neuropsychiatric Symptoms in Alzheimer Disease Over 6 Months
Ryu, S.-H., Katona, C., Rive, B., & Livingston, G. (2005) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200511000-00008 · Cited by 22 · cited 4×
“%) have neuropsychiatric symptoms such as depression, agitation, and psychosis (behavioral and psychiatric symptoms of dementia, BPSD) [174, 175].”
BackgroundInfluentialAlzheimer's disease: advances in trafficking
Mayeux, R., & Hyslop, P. S. G. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70298-3 · Cited by 20 · cited 1×
“However, when APP accumulates at the cell surface, it has a greater chance of interacting with α-secretase to form nonamyloid-forming sAPPα [136, 137].”
BackgroundRodríguez, E., Mateo, I., Llorca, J., Sánchez‐Quintana, C., Infante, J., Berciano, J., & Combarros, O. (2006) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30341 · Cited by 10
Cited by
Morris, G. P., Clark, I. A., & Vissel, B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1918-8 · Cited by 212
Elias-Sonnenschein, L. S., Helisalmi, S., Natunen, T., Hall, A., Paajanen, T., Herukka, S.-K., Laitinen, M., Remes, A. M., Koivisto, A. M., Mattila, K. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059676 · Cited by 70
“Functions of the AlzGene variants in relation to AD have been previously described [9,14,15].”
Initial Assessment of the Pathogenic Mechanisms of the Recently Identified Alzheimer Risk Loci
Holton, P., Ryten, M., Nalls, M., Trabzuni, D., Weale, M. E., Hernandez, D., Crehan, H., Gibbs, J. R., Mayeux, R., Haines, J. L., et al. (2013) · Annals of Human Genetics · doi:10.1111/ahg.12000 · Cited by 48
Metadata
- Authors
- Olgiati, P., Politis, A. M., Papadimitriou, G. N., De Ronchi, D., & Serretti, A.
- Venue
- International Journal of Alzheimer’s Disease
- Publisher
- Wiley
- Published
- 2011-01
- Volume
- 2011
- Issue
- 1
- Pages
- 832379-832379
- ISSN
- 2090-0252 (ISSN-L)
- 2090-8024
- OpenAlex
- W2127706478
- Cited by
- 57
- References
- 50
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.